Programme Overview
Advancing plasma therapeutics from early research to clinical trials
(Sami Chtourou, K2C-BIOPHARM) |
Safety, Quality and Regulatory aspects of plasma fractionation (Beatrice Biebuyck, Takeda) |
Novel technologies and solutions for plasma fractionation (Merche Faro, Grifols) |
Plasma 4.0 – digital transformation of the plasma business and manufacturing (Barbara Kalina, CSL Behring) |
Future perspectives on the plasma business and market (Eric Youssef, Cytiva) |
Next Generation Sequencing: Applications of this powerful tool for adventitious virus testing in biological products Andy Bailey, ViruSure |
Panel discussion with • • •Dr. Thomas Kriel, Head of Pathogen Safety at Takeda • •Dr. Dorothy Scott, Branch Chief, Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, FDA • •Dominika Misztela, Sr. Director, Regulatory Policy Europe at PPTA • •Saleh Yusuf, MBA, LSSBB, Director of North America Logistics, Kedrion Biopharma Inc |
Next Generation Bioprocessing Using Novel Materials and Ligand Chemistries Lynne Deakin 3M Company |
Yield optimization of plasma fraction purification using mechanistic chromatography modeling Paul Sylvain, Takeda |
The impact of Covid-19 and other events on the plasma fractionation industry - Historical Perspective and Lessons Learned (or Not) Patrick Robert, MRB |
Plasma fractionation and downstream processing of human polyclonal antibodies from the DiversitAb™ platform Christoph Bausch, SAb Biotherapeutics |
Virus inactivation by UV-C irradiation of plasma proteins Gerhard Poelsler, Biotest |
Technology Transfer during the COVID pandemic: Leveraging Communication Platforms and Mixed Reality Pushpa Kotharu, CSL Behring |
Multiple challenges impact future perspectives Jan Bult, JMB Consultancy BV |
|
Efficacy and safety of SAB-185, a novel SARS-Cov-2 Immunotherapeutic: a phase 1/1b.. Christoph Bausch, SAb Biotherapeutics |
Novel Dual Affinity Protein technology provide 80% increase in yield of IVIG Jan Kyhse-Andersen, CHRETO |
Overcoming manufacturing challenges for the super orphan plasma-derived drug BabyBIG® used to treat infant botulism Patrick Gavit, Takeda |
How plasma supply to meet the needs for plasma-derived medicines can bring value for public health systems Leni Von Bonsdorff , IPFA |
|
Next-Generation Fc Receptor–Targeting Biologics for Autoimmune Diseases Fabian Käsermann, CSL Behring |
Process Knowledge reboot: Applying QbD to legacy plasma products to modernize PPQ, Quality Management, and the regulatory dossier Patrick Gregory, CSL Behring |
Base Fractionation – Next Generation Richard Weidemann CSL Behring |
What can we expect from the plasma fractionation industry in the future? John Curling, JCC AB |